SFA Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
SFA Therapeutics, Inc is a clinical-stage, platform-based biotech with a novel small molecule immunomodulatory platform focused on chronic inflammatory and autoimmune diseases with significant unmet needs. We have World-class data for our lead asset, SFA-002, in a recently completed phase 1b clinical trial in psoriasis. This is a proof of concept for an oral drug that has the potential to become an oral Enbrel or oral Humira. This drug has shown durable effects and has data that are better in both safety and efficacy than marketed and competitive products under development.
SFA has additional drugs for pancreatic cancer, MASH/NASH, and other inflammatory diseases.
Our vision is to change Medicine.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}